Organon (OGN) Stock Rockets 41% as Sun Pharma Submits $12B Buyout Proposal

Key Highlights

• Sun Pharmaceutical Industries has put forward a binding all-cash proposal valued at $12 billion to purchase Organon (OGN)
• Organon shares rocketed 41% to reach $8.25 during Friday trading, following an 18% climb to $6.91 the previous day
• The Indian drugmaker has wrapped up more than three months of comprehensive due diligence and is securing funding through JPMorgan and MUFG
• The transaction, if finalized, would represent the biggest international merger and acquisition by an Indian pharmaceutical firm in history
• Shares of Sun Pharmaceutical declined 3% on Mumbai exchanges after the acquisition news broke

Organon has experienced an extraordinary two-day trading surge. The women’s healthcare specialist headquartered in New Jersey saw its shares climb 41% Friday morning to $8.25, building on the previous session’s 18% rally, following news that Sun Pharmaceutical Industries had delivered a formal $12 billion acquisition proposal.

Organon & Co., OGN

According to India’s Economic Times, the pharmaceutical giant based in Mumbai has progressed past the exploratory phase and presented a binding, all-cash purchase agreement. Sun Pharma’s acquisition efforts have been underway for over three months.

With Organon’s current market capitalization hovering around $1.8 billion, the proposed $12 billion transaction represents a significant premium above its present trading value.

The deal’s financial backing involves collaboration with prominent global financial institutions. Major players including JPMorgan and Japan’s MUFG are assisting Sun Pharma in structuring the necessary financing arrangements.

Organon’s Corporate History

Organon emerged as an independent entity when Merck separated the business in 2021. The company specializes in women’s reproductive health, birth control solutions, and fertility treatments, while maintaining additional product lines spanning dermatology, neurological conditions, and heart health.

The organization has navigated challenging circumstances recently. Last October, then-CEO Kevin Ali departed following an internal board inquiry that uncovered what company officials characterized as inappropriate sales tactics employed to artificially boost quarterly performance metrics.

Sun Pharma’s pursuit of Organon isn’t breaking news. Earlier in January, the Economic Times disclosed that Sun Pharma had extended a preliminary, non-binding cash proposal and was gearing up to launch due diligence procedures. Friday’s development signals meaningful progression beyond that initial phase.

Implications for Sun Pharmaceutical

Should the transaction reach completion, it would establish a new benchmark as the most substantial international acquisition in the history of India’s pharmaceutical industry.

Sun Pharmaceutical’s stock price dropped 3% on Mumbai markets Friday in response to the announcement. Such negative market reactions are typical when acquiring companies unveil large-scale, debt-financed transactions.

Both Organon and Sun Pharmaceutical declined to provide statements when contacted by media outlets regarding the reported offer.

Prior to this week’s explosive growth, OGN shares had been languishing at significantly reduced valuations. The consecutive gains of 18% and 41% mark a substantial reversal in market perception surrounding the equity.

According to Friday morning reports, Sun Pharma has entered the concluding phases of its bid process, with financial arrangements being finalized concurrently with the binding offer submission.

The post Organon (OGN) Stock Rockets 41% as Sun Pharma Submits $12B Buyout Proposal appeared first on Blockonomi.